Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 65.42 Million EUR | -9.3% |
| 2022 | 72.13 Million EUR | -1.38% |
| 2021 | 73.14 Million EUR | -0.51% |
| 2020 | 73.51 Million EUR | -13.18% |
| 2019 | 84.67 Million EUR | 147.42% |
| 2018 | 34.22 Million EUR | -20.85% |
| 2017 | 43.23 Million EUR | 27.94% |
| 2016 | 33.79 Million EUR | -21.0% |
| 2015 | 42.77 Million EUR | 17.83% |
| 2014 | 36.3 Million EUR | 17.2% |
| 2013 | 30.97 Million EUR | -19.31% |
| 2012 | 38.39 Million EUR | -6.92% |
| 2011 | 41.24 Million EUR | -4.28% |
| 2010 | 43.08 Million EUR | 42.41% |
| 2009 | 30.25 Million EUR | 16.42% |
| 2008 | 25.98 Million EUR | 17.18% |
| 2007 | 22.17 Million EUR | 82.29% |
| 2006 | 12.16 Million EUR | -99.99% |
| 2005 | 221.47 Billion EUR | 172818.43% |
| 2004 | 128.07 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 81.77 Million EUR | 24.99% |
| 2024 Q2 | 121.15 Million EUR | 48.16% |
| 2023 Q4 | 65.42 Million EUR | 2.78% |
| 2023 FY | 65.42 Million EUR | -9.3% |
| 2023 Q1 | 69.3 Million EUR | -3.93% |
| 2023 Q2 | 66.5 Million EUR | -4.05% |
| 2023 Q3 | 63.65 Million EUR | -4.28% |
| 2022 Q1 | 72.29 Million EUR | -1.17% |
| 2022 FY | 72.13 Million EUR | -1.38% |
| 2022 Q2 | 73.12 Million EUR | 1.16% |
| 2022 Q4 | 72.13 Million EUR | -2.01% |
| 2022 Q3 | 73.62 Million EUR | 0.67% |
| 2021 Q1 | 72.71 Million EUR | -1.09% |
| 2021 Q4 | 73.14 Million EUR | 1.74% |
| 2021 FY | 73.14 Million EUR | -0.51% |
| 2021 Q2 | 72.83 Million EUR | 0.16% |
| 2021 Q3 | 71.89 Million EUR | -1.29% |
| 2020 FY | 73.51 Million EUR | -13.18% |
| 2020 Q4 | 73.51 Million EUR | -1.85% |
| 2020 Q3 | 74.9 Million EUR | -0.6% |
| 2020 Q2 | 75.35 Million EUR | -1.7% |
| 2020 Q1 | 76.65 Million EUR | -9.47% |
| 2019 Q4 | 84.67 Million EUR | 90.94% |
| 2019 Q1 | 50.75 Million EUR | 48.3% |
| 2019 FY | 84.67 Million EUR | 147.42% |
| 2019 Q2 | 49.07 Million EUR | -3.31% |
| 2019 Q3 | 44.34 Million EUR | -9.63% |
| 2018 FY | 34.22 Million EUR | -20.85% |
| 2018 Q3 | 39.51 Million EUR | 103.82% |
| 2018 Q2 | 19.38 Million EUR | -52.03% |
| 2018 Q1 | 40.42 Million EUR | -6.52% |
| 2018 Q4 | 34.22 Million EUR | -13.4% |
| 2017 Q4 | 43.23 Million EUR | -8.21% |
| 2017 FY | 43.23 Million EUR | 27.94% |
| 2017 Q3 | 47.1 Million EUR | -4.13% |
| 2017 Q2 | 49.13 Million EUR | -4.22% |
| 2017 Q1 | 51.3 Million EUR | 51.8% |
| 2016 Q1 | 41.44 Million EUR | -3.12% |
| 2016 Q2 | 39.72 Million EUR | -4.15% |
| 2016 Q3 | 37.62 Million EUR | -5.27% |
| 2016 Q4 | 33.79 Million EUR | -10.19% |
| 2016 FY | 33.79 Million EUR | -21.0% |
| 2015 Q4 | 42.77 Million EUR | -3.1% |
| 2015 Q2 | 35.03 Million EUR | -2.51% |
| 2015 Q3 | 44.14 Million EUR | 26.0% |
| 2015 Q1 | 35.93 Million EUR | -1.01% |
| 2015 FY | 42.77 Million EUR | 17.83% |
| 2014 Q3 | 37.29 Million EUR | 47.91% |
| 2014 Q2 | 25.21 Million EUR | -16.59% |
| 2014 Q4 | 36.3 Million EUR | -2.65% |
| 2014 FY | 36.3 Million EUR | 17.2% |
| 2014 Q1 | 30.22 Million EUR | -2.42% |
| 2013 Q4 | 30.97 Million EUR | -1.74% |
| 2013 Q3 | 31.52 Million EUR | -1.64% |
| 2013 Q2 | 32.05 Million EUR | -15.84% |
| 2013 Q1 | 38.08 Million EUR | -0.79% |
| 2013 FY | 30.97 Million EUR | -19.31% |
| 2012 Q1 | 43.93 Million EUR | 6.51% |
| 2012 Q4 | 38.39 Million EUR | -0.32% |
| 2012 Q3 | 38.51 Million EUR | 923.79% |
| 2012 FY | 38.39 Million EUR | -6.92% |
| 2012 Q2 | 3.76 Million EUR | -91.44% |
| 2011 Q3 | 51.84 Million EUR | 18.6% |
| 2011 FY | 41.24 Million EUR | -4.28% |
| 2011 Q4 | 41.24 Million EUR | -20.45% |
| 2011 Q2 | 43.71 Million EUR | -3.76% |
| 2011 Q1 | 45.42 Million EUR | 5.43% |
| 2010 FY | 43.08 Million EUR | 42.41% |
| 2010 Q4 | 43.08 Million EUR | 0.0% |
| 2009 FY | 30.25 Million EUR | 16.42% |
| 2008 FY | 25.98 Million EUR | 17.18% |
| 2007 FY | 22.17 Million EUR | 82.29% |
| 2006 FY | 12.16 Million EUR | -99.99% |
| 2005 FY | 221.47 Billion EUR | 172818.43% |
| 2004 FY | 128.07 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -58.792% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -1487.28% |
| SQZ Biotechnologies Company | 27.47 Million USD | -138.168% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -50.847% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -119.796% |
| Mesoblast Limited | 118.7 Million USD | 44.881% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -6799.61% |
| Genus plc | 233.1 Million USD | 71.932% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -2132.708% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -4769.588% |
| Marizyme, Inc. | 18.71 Million USD | -249.55% |
| ContraFect Corporation | 2.88 Million USD | -2170.982% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -8623.6% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -48190.242% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -4423.691% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -2712.909% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -1056.291% |
| MultiCell Technologies, Inc. | 202.58 USD | -32296770.372% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -13.808% |
| EV Biologics, Inc. | 1.49 Million USD | -4277.117% |
| Q BioMed Inc. | 4.1 Million USD | -1491.905% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -97.659% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -10283.969% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -5226.366% |
| Biomind Labs Inc. | 735.54 Thousand USD | -8795.073% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 61.86% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -403.401% |
| Skye Bioscience, Inc. | 4.61 Million USD | -1317.621% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -7267.374% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -46132.281% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -1014.393% |
| IMV Inc. | 28.88 Million USD | -126.517% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -254291.695% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -2797.075% |
| GB Sciences, Inc. | 1.75 Million USD | -3618.908% |
| Alpha Cognition Inc. | 1.22 Million USD | -5261.234% |
| HST Global, Inc. | 98.31 Thousand USD | -66445.632% |
| CSL Limited | 12.18 Billion USD | 99.463% |
| Halberd Corporation | 150 Thousand USD | -43518.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -6466.747% |
| Resverlogix Corp. | 6.49 Million USD | -907.965% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -13601.99% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -25498.219% |
| argenx SE | 20 Million USD | -227.135% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -43.606% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -2315.436% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -639772.861% |
| Genscript Biotech Corporation | 417.73 Million USD | 84.338% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -32513.052% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -2628.713% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -28434.482% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 3.276% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -2062.025% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -18088.819% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -221.857% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -43912.943% |
| BioStem Technologies, Inc. | 4.71 Million USD | -1288.69% |
| ONE Bio Corp. | 19.71 Million USD | -231.864% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -26051.762% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -26205.484% |
| Agentix Corp. | 50 Thousand USD | -130754.0% |
| LadRx Corporation | 33.6 Thousand USD | -194588.448% |
| Cell Source, Inc. | 9.25 Million USD | -607.0% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -8552.03% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -8552.03% |
| NovAccess Global Inc. | 2.19 Million USD | -2874.117% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -825.05% |
| Itoco Inc. | 228.37 Thousand USD | -28548.682% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -30911.731% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -1213.004% |
| Kadimastem Ltd | 891.22 Thousand USD | -7241.236% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -16181.489% |
| CytoDyn Inc. | 30.07 Million USD | -117.539% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -13410.048% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -18495.299% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -736.667% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -53309.796% |
| Rebus Holdings, Inc. | 310 Thousand USD | -21005.484% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -1281.692% |
| International Stem Cell Corporation | 4.17 Million USD | -1465.989% |
| Bioxytran, Inc. | 1.92 Million USD | -3298.805% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -104729.122% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -2900.0% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -686.76% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -662.108% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -4106.228% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -24313.06% |
| Neutra Corp. | 54.15 Thousand USD | -120712.098% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -3475.246% |
| PureTech Health plc | 25.51 Million USD | -156.456% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -5244.356% |
| IXICO plc | 472.02 Thousand USD | -13760.977% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -322.082% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -5.082% |
| CSL Limited | 12.18 Billion USD | 99.463% |
| Cellectis S.A. | 92.77 Million USD | 29.479% |